RAPT Therapeutics, Inc.

NasdaqGM:RAPT Stock Report

Market Cap: US$278.4m

RAPT Therapeutics Management

Management criteria checks 2/4

RAPT Therapeutics' CEO is Brian Wong, appointed in Aug 2015, has a tenure of 8.67 years. total yearly compensation is $6.59M, comprised of 9.2% salary and 90.8% bonuses, including company stock and options. directly owns 1.42% of the company’s shares, worth $3.94M. The average tenure of the management team and the board of directors is 4.2 years and 6.9 years respectively.

Key information

Brian Wong

Chief executive officer

US$6.6m

Total compensation

CEO salary percentage9.2%
CEO tenure8.7yrs
CEO ownership1.4%
Management average tenure4.2yrs
Board average tenure6.9yrs

Recent management updates

Recent updates

Is RAPT Therapeutics (NASDAQ:RAPT) In A Good Position To Invest In Growth?

Feb 21
Is RAPT Therapeutics (NASDAQ:RAPT) In A Good Position To Invest In Growth?

We Think RAPT Therapeutics (NASDAQ:RAPT) Can Afford To Drive Business Growth

Sep 12
We Think RAPT Therapeutics (NASDAQ:RAPT) Can Afford To Drive Business Growth

We Think RAPT Therapeutics (NASDAQ:RAPT) Can Afford To Drive Business Growth

May 10
We Think RAPT Therapeutics (NASDAQ:RAPT) Can Afford To Drive Business Growth

We're Hopeful That RAPT Therapeutics (NASDAQ:RAPT) Will Use Its Cash Wisely

Feb 07
We're Hopeful That RAPT Therapeutics (NASDAQ:RAPT) Will Use Its Cash Wisely

We're Hopeful That RAPT Therapeutics (NASDAQ:RAPT) Will Use Its Cash Wisely

Oct 12
We're Hopeful That RAPT Therapeutics (NASDAQ:RAPT) Will Use Its Cash Wisely

RAPT Therapeutics (NASDAQ:RAPT) Is In A Good Position To Deliver On Growth Plans

Jan 25
RAPT Therapeutics (NASDAQ:RAPT) Is In A Good Position To Deliver On Growth Plans

RAPT Therapeutics (NASDAQ:RAPT) Is In A Good Position To Deliver On Growth Plans

Oct 15
RAPT Therapeutics (NASDAQ:RAPT) Is In A Good Position To Deliver On Growth Plans

RAPT Therapeutics (RAPT) skyrockets 100% on positive RPT193 data in early-stage atopic dermatitis study

Jun 14

RAPT Therapeutics (NASDAQ:RAPT) Is In A Good Position To Deliver On Growth Plans

Jun 08
RAPT Therapeutics (NASDAQ:RAPT) Is In A Good Position To Deliver On Growth Plans

Should You Take Comfort From Insider Transactions At RAPT Therapeutics, Inc. (NASDAQ:RAPT)?

Mar 15
Should You Take Comfort From Insider Transactions At RAPT Therapeutics, Inc. (NASDAQ:RAPT)?

We Think RAPT Therapeutics (NASDAQ:RAPT) Can Easily Afford To Drive Business Growth

Feb 15
We Think RAPT Therapeutics (NASDAQ:RAPT) Can Easily Afford To Drive Business Growth

RAPT Therapeutics' (NASDAQ:RAPT) Stock Price Has Reduced 56% In The Past Year

Jan 18
RAPT Therapeutics' (NASDAQ:RAPT) Stock Price Has Reduced 56% In The Past Year

RAPT Therapeutics: Interesting Asset, But Doubtful History And Bad Market Reaction

Jan 08

Here's What RAPT Therapeutics, Inc.'s (NASDAQ:RAPT) Shareholder Ownership Structure Looks Like

Dec 21
Here's What RAPT Therapeutics, Inc.'s (NASDAQ:RAPT) Shareholder Ownership Structure Looks Like

The Independent Chairman of the Board of RAPT Therapeutics, Inc. (NASDAQ:RAPT), William Rieflin, Just Bought 12% More Shares

Nov 23
The Independent Chairman of the Board of RAPT Therapeutics, Inc. (NASDAQ:RAPT), William Rieflin, Just Bought 12% More Shares

Earnings Beat: RAPT Therapeutics, Inc. (NASDAQ:RAPT) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

Nov 19
Earnings Beat: RAPT Therapeutics, Inc. (NASDAQ:RAPT) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

RAPT Therapeutics tumbles 25% despite promising FLX475 data in multiple cancers

Nov 16

CEO Compensation Analysis

How has Brian Wong's remuneration changed compared to RAPT Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2023US$7mUS$605k

-US$117m

Sep 30 2023n/an/a

-US$109m

Jun 30 2023n/an/a

-US$99m

Mar 31 2023n/an/a

-US$93m

Dec 31 2022US$5mUS$580k

-US$84m

Sep 30 2022n/an/a

-US$79m

Jun 30 2022n/an/a

-US$76m

Mar 31 2022n/an/a

-US$73m

Dec 31 2021US$3mUS$540k

-US$69m

Sep 30 2021n/an/a

-US$64m

Jun 30 2021n/an/a

-US$60m

Mar 31 2021n/an/a

-US$56m

Dec 31 2020US$4mUS$500k

-US$53m

Sep 30 2020n/an/a

-US$53m

Jun 30 2020n/an/a

-US$49m

Mar 31 2020n/an/a

-US$47m

Dec 31 2019US$2mUS$447k

-US$43m

Sep 30 2019n/an/a

-US$39m

Jun 30 2019n/an/a

-US$40m

Mar 31 2019n/an/a

-US$37m

Dec 31 2018US$1mUS$425k

-US$36m

Compensation vs Market: Brian's total compensation ($USD6.59M) is above average for companies of similar size in the US market ($USD1.63M).

Compensation vs Earnings: Brian's compensation has increased whilst the company is unprofitable.


CEO

Brian Wong (51 yo)

8.7yrs

Tenure

US$6,591,617

Compensation

Dr. Brian Russell Wong, M.D., Ph.D. serves as Venture Partner at The Column Group, LLC since joining the firm in 2022. He has been Chief Executive Officer and Director at RAPT Therapeutics, Inc. since Augu...


Leadership Team

NamePositionTenureCompensationOwnership
Brian Wong
CEO, President & Director8.7yrsUS$6.59m1.42%
$ 3.9m
Rodney K. Young
CFO, Principal Accounting Officer & Secretary4.3yrsUS$2.18m0.034%
$ 93.8k
William Ho
Chief Medical Officer8.9yrsUS$1.90m0.045%
$ 125.9k
Steve Young
Vice President of Technologyno datano datano data
Dirk Brockstedt
Chief Scientific Officer4.8yrsUS$1.48m0.074%
$ 206.6k
Michael Listgarten
General Counsel1.3yrsno datano data
Gwen Carscadden
Chief Human Resources Officer1.9yrsno datano data
Paul Kassner
Senior Vice President of Quantitative & Computational Biology4.1yrsno datano data
David Wustrow
Senior Vice President of Drug Discovery & Preclinical Development5.3yrsno datano data
Jennifer Nicholson
Senior Vice President of Regulatory Affairs & Quality Assurance1.6yrsno datano data
Nipun Davar
Senior Vice President of Technical Operationsless than a yearno datano data

4.2yrs

Average Tenure

56.5yo

Average Age

Experienced Management: RAPT's management team is considered experienced (4.2 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Brian Wong
CEO, President & Director8.7yrsUS$6.59m1.42%
$ 3.9m
William Rieflin
Independent Chairman of the Board8.9yrsUS$175.46k0.27%
$ 757.8k
Mary Gray
Independent Director4.3yrsUS$152.96k0%
$ 0
Drew Pardoll
Member of Scientific Advisory Board6.9yrsno datano data
Philip Greenberg
Member of Scientific Advisory Board6.9yrsno datano data
Alexander Rudensky
Chairman of Scientific Advisory Boardno datano datano data
Antoni Ribas
Member of Scientific Advisory Boardno datano datano data
Scott Antonia
Member of Scientific Advisory Board6.6yrsno datano data
Emma Guttman-Yassky
Member of Scientific Advisory Board4.8yrsno datano data
Michael Giordano
Independent Director6.3yrsUS$267.78k0%
$ 0
Linda Kozick
Independent Director7.3yrsUS$260.78k0%
$ 0
Robert Zamboni
Member of Scientific Advisory Boardno datano datano data

6.9yrs

Average Tenure

64yo

Average Age

Experienced Board: RAPT's board of directors are considered experienced (6.9 years average tenure).


Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.